Cases from the Community: Investigators Discuss Emerging Research and Actual Patients with Renal Cell Carcinoma (Webinar Audio Proceedings)
Released April 2021
Featuring perspectives from Dr Thomas E Hutson and Prof Thomas Powles. (Audio Program)
This activity has been designed to meet the educational needs of medical and radiation oncologists, urologists and other allied healthcare professionals involved in the treatment of renal cell carcinoma (RCC).
Effectively apply evidence-based research findings and other clinical and biologic factors in the best-practice selection of first-line therapy for patients with metastatic renal cell carcinoma (mRCC).
Recall the underlying research database supporting the FDA approval of anti-PD-1/anti-CTLA-4 combination therapy as first-line treatment for mRCC, and develop strategies to appropriately integrate this approach into patient care.
Appraise available clinical trial data evaluating combinations of anti-PD-1/PD-L1 antibodies with multikinase inhibitors for previously untreated mRCC, and counsel patients regarding the risks and benefits of these novel regimens.
Develop a rational approach to the sequencing of systemic therapies for patients with advanced RCC that progresses on first-line treatment, incorporating multikinase inhibitors, mTOR inhibitors, immunotherapeutic agents and other therapies.
Recognize side effects and toxicities commonly associated with approved and investigational therapeutic approaches, and use this information to develop supportive care plans for patients with RCC undergoing treatment with these agents and regimens.
Recall available and emerging data with other investigational agents and strategies currently in testing for RCC, and appropriately refer eligible patients for clinical trial participation.
CME credit is no longer available for this issue
Audio Program: This CME activity consists of an audio component.
Video Program: This CME activity consists of a video component.
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — The following faculty reported relevant conflicts of interest, which have been mitigated through a conflict of interest mitigation process:
Thomas E Hutson, DO, PharmD
Director, GU Oncology Program
Co-Director, Urologic Cancer Research and Treatment Center
Charles A Sammons Cancer Center
Baylor University Medical Center
Texas A&M HSC College of Medicine
No financial interests or affiliations to disclose.
Thomas Powles, MBBS, MRCP, MD
Professor of Genitourinary Oncology
Barts Cancer Institute
Director of Barts Cancer Centre
Advisory Committee: Astellas, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eisai Inc, Exelixis Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Johnson & Johnson Pharmaceuticals, Merck, Merck Serono, Merck Sharp & Dohme Corp, Novartis, Pfizer Inc, Roche Laboratories Inc, Seagen Inc; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eisai Inc, Exelixis Inc, Ipsen Biopharmaceuticals Inc, Johnson & Johnson Pharmaceuticals, Merck, Merck Serono, Merck Sharp & Dohme Corp, Novartis, Pfizer Inc, Roche Laboratories Inc, Seagen Inc; Travel/Accommodation/Expenses: AstraZeneca Pharmaceuticals LP, Ipsen Biopharmaceuticals Inc, Merck Sharp & Dohme Corp, Pfizer Inc, Roche Laboratories Inc.
MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Turning Point Therapeutics Inc and Verastem Inc.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.
This activity is supported by an educational grant from Exelixis Inc.
Expiration date: April 2022
Front-line treatment of advanced renal cell carcinoma (RCC)
Case: A 53-year-old man with RCC initially treated as head and neck carcinoma — Syed F Zafar, MD
Case: A 67-year-old man with metastatic RCC — Rahul Gosain, MD
Case: A 60-year-old man with Stage IV clear cell RCC — Kelly Yap, MD
Case: An 85-year-old man with metastatic RCC — Dr Zafar
Sequencing of therapies for relapsed/refractory RCC
Novel approaches for advanced RCC